



Attorney Docket No.: 4318.234-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bisgaard-Frantzen et al.

Confirmation No: 8501

Serial No.: 10/025,648

Group Art Unit: 1751

Filed: December 19, 2001

Examiner: Prouty

For: Amylase Variants

TRANSMITTAL OF CERTIFIED COPY OF PRIORITY APPLICATION(S)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Attached please find certified copies of foreign applications from which priority is claimed for this case:

Country: Denmark  
Application Number: PA 1995 00126  
Filing Date: February 3, 1995

Country: Denmark  
Application Number: PA 01097  
Filing Date: September 29, 1995

Country: Denmark  
Application Number: PA 1995 01121  
Filing Date: October 6, 1995

Country: Denmark  
Application Number: PA 1995 00336  
Filing Date: March 29, 1995

Respectfully submitted,

Date: September 29, 2004

Jason I. Garbell, Reg. No. 44,116  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212) 840-0097



# Kongeriget Danmark

Patent application No.: PA 1995 00126

Date of filing: 03 February 1995

Applicant: \_\_\_\_\_ Novo Nordisk A/S  
(Name and address) \_\_\_\_\_ Novo Allé  
DK-2880 Bagsværd  
Denmark

Title: Amylase variants

IPC: -

**CERTIFIED COPY OF  
PRIORITY DOCUMENT**

This is to certify that the attached documents are exact copies of the above mentioned patent application as originally filed.

**BEST AVAILABLE COPY**

**Patent- og Varemærkestyrelsen**  
Økonomi- og Erhvervsministeriet

27 September 2004

  
Pia Høybye-Olsen

PATENT- OG VAREMÆRKESTYRELSEN



## AMYLASE VARIANTS

### FIELD OF THE INVENTION

The present invention relates to  $\alpha$ -amylase variants having improved properties relative to the parent enzyme (e.g. improved thermal and/or oxidation stability  
5 and/or reduced calcium ion dependency), and thereby improved washing and/or dishwashing (and/or textile desizing) performance. The invention also relates to DNA constructs encoding the variants, and to vectors and cells harbouring the DNA constructs. The invention further relates to methods of producing the amylase variants, and to detergent additives and detergent compositions  
10 comprising the amylase variants. Furthermore, the invention relates to the use of the amylase variants for textile desizing.

### BACKGROUND OF THE INVENTION

For a number of years  $\alpha$ -amylase enzymes have been used for a variety of different purposes, the most important of which are starch liquefaction, textile  
15 desizing, starch modification in the paper and pulp industry, and for brewing and baking. A further use of  $\alpha$ -amylases, which is becoming increasingly important, is the removal of starchy stains during washing or dishwashing.

In recent years attempts have been made to construct  $\alpha$ -amylase variants having improved properties with respect to specific uses such as starch liquefaction and  
20 textile desizing.

For instance, US 5,093,257 discloses chimeric  $\alpha$ -amylases comprising an N-terminal part of a *B. stearothermophilus*  $\alpha$ -amylase and a C-terminal part of a *B. licheniformis*  $\alpha$ -amylase. The chimeric  $\alpha$ -amylases are stated to have unique properties, such as a different thermostability, as compared to their parent  
25  $\alpha$ -amylase. However, all of the specifically described chimeric  $\alpha$ -amylases were

shown to have a decreased enzymatic activity as compared to their parent  $\alpha$ -amylases.

EP 252 666 describes hybrid amylases of the general formula Q-R-L, in which Q is a N-terminal polypeptide residue of from 55 to 60 amino acid residues which is at least 75% homologous to the 57 N-terminal amino acid residues of a specified  $\alpha$ -amylase from *B. amyloliquefaciens*, R is a specified polypeptide, and L is a C-terminal polypeptide comprising from 390 to 400 amino acid residues which is at least 75% homologous to the 395 C-terminal amino acid residues of a specified *B. licheniformis*  $\alpha$ -amylase.

10 Suzuki et al. (1989) disclose chimeric  $\alpha$ -amylases, in which specified regions of a *B. amyloliquefaciens*  $\alpha$ -amylase have been substituted for the corresponding regions of a *B. licheniformis*  $\alpha$ -amylase. The chimeric  $\alpha$ -amylases were constructed with the purpose of identifying regions responsible for thermostability. Such regions were found to include amino acid residues 177-186 and  
15 amino acid residues 255-270 of the *B. amyloliquefaciens*  $\alpha$ -amylase. The alterations of amino acid residues in the chimeric  $\alpha$ -amylases did not seem to affect properties of the enzymes other than their thermostability.

WO 91/00353 discloses  $\alpha$ -amylase mutants which differ from their parent  $\alpha$ -amylase in at least one amino acid residue. The  $\alpha$ -amylase mutants disclosed  
20 in said patent application are stated to exhibit improved properties for application in the degradation of starch and/or textile desizing due to their amino acid substitutions. Some of the mutants exhibit improved stability, but no improvements in enzymatic activity were reported or indicated. The only mutants exemplified are prepared from a parent *B. licheniformis*  $\alpha$ -amylase and carry one  
25 of the following mutations: H133Y or H133Y + T149I. Another suggested mutation is A111T.

FR 2,676,456 discloses mutants of the *B. licheniformis*  $\alpha$ -amylase, in which an amino acid residue in the proximity of His 133 and/or an amino acid residue in the

proximity of Ala 209 have been replaced by a more hydrophobic amino acid residue. The resulting  $\alpha$ -amylase mutants are stated to have an improved thermostability and to be useful in the textile, paper, brewing and starch liquefaction industry.

- 5 EP 285 123 discloses a method of performing random mutagenesis of a nucleotide sequence. As an example of such sequence a nucleotide sequence encoding a *B. stearothermophilus*  $\alpha$ -amylase is mentioned. When mutated, an  $\alpha$ -amylase variant having improved activity at low pH values is obtained.

In none of the above references is it mentioned or even suggested that  $\alpha$ -amylase  
10 mutants may be constructed which have improved properties with respect to the detergent industry.

EP 525 610 relates to mutant enzymes having an improved stability towards ionic tensides. The mutant enzymes have been produced by replacing an amino acid residue in the surface part of the parent enzyme with another amino acid  
15 residue. The only mutant enzyme specifically described in EP 525 610 is a protease. Amylase is mentioned as an example of an enzyme which may obtain an improved stability towards ionic tensides, but the type of amylase, its origin or specific mutations are not specified.

WO 94/02597 discloses  $\alpha$ -amylase mutants which exhibit an improved stability  
20 and activity in the presence of oxidizing agents. In the mutant  $\alpha$ -amylases, one or more methionine residues have been replaced with amino acid residues different from Cys and Met. The  $\alpha$ -amylase mutants are stated to be useful as detergent and/or dishwashing additives as well as for textile desizing.

WO 94/18314 discloses oxidatively stable  $\alpha$ -amylase mutants, including  
25 mutations in the M197 position of *B. licheniformis*  $\alpha$ -amylase.

EP 368 341 describes the use of pullulanase and other amylolytic enzymes optionally in combination with an  $\alpha$ -amylase for washing and dishwashing.

An object of the present invention is to provide  $\alpha$ -amylase variants which - relative to their parent  $\alpha$ -amylase - possess improved properties of importance, inter alia, in relation to the washing and/or dishwashing performance of the variants in question, e.g. increased thermal stability, increased stability towards oxidation, reduced dependency on  $\text{Ca}^{2+}$  ion and/or improved stability or activity in the pH region of relevance in, e.g., laundry washing or dishwashing. Such variant  $\alpha$ -amylases have the advantage, among others, that they may be employed in a lower dosage than their parent  $\alpha$ -amylase. Furthermore, the  $\alpha$ -amylase variants may be able to remove starchy stains which cannot, or can only with difficulty, be removed by  $\alpha$ -amylase detergent enzymes known today.

#### BRIEF DISCLOSURE OF THE INVENTION

A goal of the work underlying the present invention was to improve, if possible, the stability of a particular  $\alpha$ -amylase which is obtainable from a *Bacillus* strain and which itself had been selected on the basis of its improved starch removal performance in alkaline media (such as in detergent solutions as typically employed in laundry washing or dishwashing) relative to many of the currently commercially available  $\alpha$ -amylases. In this connection, the present inventors have surprisingly found that it is in fact possible to improve properties of the types mentioned earlier (*vide supra*) of such a parent  $\alpha$ -amylase by judicial modification of one or more amino acid residues in various regions of the amino acid sequence of the parent  $\alpha$ -amylase. The present invention is based on this finding.

Accordingly, in a first aspect the present invention relates to variants of a parent  $\alpha$ -amylase, the parent  $\alpha$ -amylase in question being one which: has the amino acid sequence shown in SEQ ID No. 1 herein; or displays at least 80% homology with the latter amino acid sequence, and/or displays immunological cross-reactivity with an antibody raised against the  $\alpha$ -amylase having the latter amino acid

sequence, and/or is encoded by a DNA sequence which hybridizes with the same probe as the DNA sequence encoding an  $\alpha$ -amylase having said amino acid sequence, which latter DNA sequence is shown in SEQ ID No. 1. The variants in question are variants in which: (a) at least one amino acid residue of the parent  $\alpha$ -amylase has been deleted; and/or (b) at least one amino acid residue of the parent  $\alpha$ -amylase has been replaced by a different amino acid residue; and/or (c) at least one amino acid residue has been inserted relative to the parent  $\alpha$ -amylase. The variants in question have themselves  $\alpha$ -amylase activity and exhibit at least one of the following properties relative to the parent  $\alpha$ -amylase:

10 increased thermostability, i.e. satisfactory retention of enzymatic activity at a temperature higher than that suitable for use with the parent enzyme;

increased oxidation stability, i.e. increased resistance to degradation by oxidants (such as oxygen, oxidizing bleaching agents and the like); and

reduced  $\text{Ca}^{2+}$  dependency, i.e. the ability to function satisfactorily in the presence of a lower  $\text{Ca}^{2+}$  concentration than in the case of the parent  $\alpha$ -amylase.  $\alpha$ -Amylases with such reduced  $\text{Ca}^{2+}$  dependency are highly desirable for use in detergent compositions, since such compositions typically contain relatively large amounts of substances (such as phosphates, EDTA and the like) which bind calcium ions strongly.

20 Examples of other desirable improvements which may be achieved with a variant according to the invention are an increase in the stability or  $\alpha$ -amylolytic activity at relatively high pH values, e.g. at pH values in the range of 8.5-10.5.

In the context of the present invention, "improved performance" as used in connection with washing and dishwashing is, as already indicated above, intended to mean improved removal of starchy stains, i.e. stains containing starch, during washing or dishwashing, respectively. The performance may be determined in conventional washing and dishwashing experiments and the improvement eval-

uated as a comparison with the performance of the parent  $\alpha$ -amylase in question. An example of a small-scale "mini dishwashing test" which can be used as an indicator of dishwashing performance is described in the Experimental section, below.

- 5 It will be understood that a variety of different characteristics of the  $\alpha$ -amylase variant, including specific activity, substrate specificity,  $K_m$ ,  $V_{max}$ ,  $pI$ ,  $pH$  optimum, temperature optimum, thermoactivation, stability towards oxidants and detergents, etc., taken alone or in combination are involved in providing the improved performance. The skilled person will be aware that the performance of  
10 the variant cannot, alone, be predicted on the basis of the above characteristics, but would have to be accompanied by washing and/or dishwashing performance tests.

In further aspects the invention relates to a DNA construct comprising a DNA sequence encoding an  $\alpha$ -amylase variant of the invention, a recombinant  
15 expression vector carrying the DNA construct, a cell which is transformed with the DNA construct or the vector, as well as a method of producing an  $\alpha$ -amylase variant by culturing such a cell under conditions conducive to the production of the  $\alpha$ -amylase variant, after which the  $\alpha$ -amylase variant is recovered from the culture.

- 20 In a further aspect the invention relates to a method of preparing a variant of a parent  $\alpha$ -amylase which by virtue of its improved properties as described above exhibits improved washing and/or dishwashing performance as compared to the parent  $\alpha$ -amylase. This method comprises

- a) constructing a population of cells containing genes encoding variants of said  
25 parent  $\alpha$ -amylase,  
b) screening the population of cells for  $\alpha$ -amylase activity under conditions simulating at least one washing and/or dishwashing condition,



- c) isolating a cell from the population containing a gene encoding a variant of said parent  $\alpha$ -amylase which has improved activity as compared with the parent  $\alpha$ -amylase under the conditions selected in step b),
- d) culturing the cell isolated in step c) under suitable conditions in an appropriate
- 5 culture medium, and
- e) recovering the  $\alpha$ -amylase variant from the culture obtained in step d).

The invention also relates to a variant (which is a variant according the invention) prepared by the latter method.

In the present context, the term "simulating at least one washing and/or  
10 dishwashing condition" is intended to indicate a simulation of, e.g., the temperature or pH prevailing during washing or dishwashing, as well as the chemical composition of a detergent composition to be used in the washing or dishwashing treatment. The term "chemical composition" is intended to include one, or a combination of two or more, constituents of the detergent composition  
15 in question. The constituents of a number of different detergent compositions are listed further below.

The "population of cells" referred to in step a) may suitably be constructed by cloning a DNA sequence encoding a parent  $\alpha$ -amylase and subjecting the DNA to site-directed or random mutagenesis as described herein.

20 In the present context the term "variant" is used interchangeably with the term "mutant". The term "variant" is intended to include hybrid  $\alpha$ -amylases, i.e.  $\alpha$ -amylases comprising parts of at least two different  $\alpha$ -amylolytic enzymes. Thus, such a hybrid may be constructed, e.g., from: one or more parts each deriving from a variant as already defined above; or one or more parts each deriving from  
25 a variant as already defined above, and one or more parts each deriving from an unmodified parent  $\alpha$ -amylase. In this connection, the invention also relates to a method of producing such a hybrid  $\alpha$ -amylase having improved washing and/or dishwashing performance as compared to any of its constituent enzymes (i.e as

compared to any of the enzymes which contribute a part to the hybrid), which method comprises:

- a) recombining *in vivo* or *in vitro* the N-terminal coding region of an  $\alpha$ -amylase gene or corresponding cDNA of one of the constituent  $\alpha$ -amylases with the C-terminal coding region of an  $\alpha$ -amylase gene or corresponding cDNA of another constituent  $\alpha$ -amylase to form recombinants,
- b) selecting recombinants that produce a hybrid  $\alpha$ -amylase having improved washing and/or dishwashing performance as compared to any of its constituent  $\alpha$ -amylases,
- 10 c) culturing recombinants selected in step b) under suitable conditions in an appropriate culture medium, and
- d) recovering the hybrid  $\alpha$ -amylase from the culture obtained in step c).

In further aspects the invention relates to the use of an  $\alpha$ -amylase variant of the invention [including any variant or hybrid prepared by one of the above mentioned  
15 methods] as a detergent enzyme, in particular for washing or dishwashing, to a detergent additive and a detergent composition comprising the  $\alpha$ -amylase variant, and to the use of an  $\alpha$ -amylase variant of the invention for textile desizing.

Random mutagenesis may be used to generate variants according to the invention, and the invention further relates to a method of preparing a variant of  
20 a parent  $\alpha$ -amylase, which method comprises

- (a) subjecting a DNA sequence encoding the parent  $\alpha$ -amylase to random mutagenesis,
- (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and
- (c) screening for host cells expressing a mutated amylolytic enzyme which has  
25 improved properties as described above (e.g. properties such as decreased calcium dependency, increased oxidation stability, increased thermostability,

and/or improved activity at relatively high pH) as compared to the parent  $\alpha$ -amylase.

## DETAILED DISCLOSURE OF THE INVENTION

### Nomenclature

5 In the present description and claims, the conventional one-letter codes for nucleotides and the conventional one-letter and three-letter codes for amino acid residues are used. For ease of reference,  $\alpha$ -amylase variants of the invention are described by use of the following nomenclature:

Original amino acid(s):position(s):substituted amino acid(s)

10

According to this nomenclature, and by way of example, the substitution of alanine for asparagine in position 30 is shown as:

Ala 30 Asn or A30N

a deletion of alanine in the same position is shown as:

15

Ala 30 \* or A30\*

and insertion of an additional amino acid residue, such as lysine, is shown as:

Ala 30 AlaLys or A30AK

A deletion of a consecutive stretch of amino acid residues, exemplified by amino acid residues 30-33, is indicated as (30-33)\*.

20 Where a specific  $\alpha$ -amylase contains a "deletion" (i.e. lacks an amino acid residue) in comparison with other  $\alpha$ -amylases and an insertion is made in such a position, this is indicated as:

\* 36 Asp or \*36D

for insertion of an aspartic acid in position 36

25 Multiple mutations are separated by plus signs, i.e.:

Ala 30 Asp + Glu 34 Ser or A30N+E34S

representing mutations in positions 30 and 34 (in which alanine and glutamic acid replace, i.e. are substituted for, asparagine and serine, respectively).

When one or more alternative amino acid residues may be inserted in a given position this is indicated as:

5 A30N,E or  
A30N or A30E

Furthermore, when a position suitable for modification is identified herein without any specific modification being suggested, it is to be understood that any amino acid residue may be substituted for the amino acid residue present in that  
10 position. Thus, for instance, when a modification (replacement) of a methionine in position 202 is mentioned, but not specified, it is to be understood any of the other amino acids may be substituted for the methionine, i.e. any other amino acid chosen among A,R,N,D,C,Q,E,G,H,I,L,K,F,P,S,T,W,Y,V.

#### The parent $\alpha$ -amylase

15 As already indicated, an  $\alpha$ -amylase variant of the invention is very suitably prepared on the basis of a parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 (*vide infra*). The latter parent  $\alpha$ -amylase is obtainable from an alkaliphilic *Bacillus* strain [strain NCIB 12289; described in detail in EP 0 277 216 B1 and deposited in accordance with the Budapest Treaty on 8 July 1986  
20 at the National Collection of Industrial Bacteria (NCIB) under accession No. NCIB 12289], and its preparation from that source is described in greater detail in the Experimental section herein (*vide infra*).

Apart from variants of the above-mentioned parent  $\alpha$ -amylase which has the amino acid sequence shown in SEQ ID No. 1, other interesting variants according  
25 to the invention include variants of parent  $\alpha$ -amylases which have amino acid sequences exhibiting a high degree of homology, such as at least 70% homology, preferably (as already indicated) at least 80% homology, and more preferably at least 90% homology, with the amino acid sequence shown in SEQ ID No. 1.

As also already indicated above, further criteria for identifying a suitable parent  $\alpha$ -amylases are a) that the  $\alpha$ -amylase displays an immunological cross-reaction with an antibody raised against the above-mentioned  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1, and/or b) that the  $\alpha$ -amylase is encoded  
5 by a DNA sequence which hybridizes with the same probe as the DNA sequence encoding an  $\alpha$ -amylase having said amino acid sequence, which latter DNA sequence is shown in SEQ ID No. 1.

With regard to determination of the degree of homology of polypeptides (such as enzymes), amino acid sequence comparisons can be performed using known  
10 algorithms, such as the one described by Lipman and Pearson (1985).

Assays for immunological cross-reactivity may be carried out using an antibody raised against, or reactive with, at least one epitope of the  $\alpha$ -amylase having the the amino acid sequence shown in SEQ ID No. 1. The antibody, which may either be monoclonal or polyclonal, may be produced by methods known in the art, e.g.  
15 as described by Hudson et al., 1989. Examples of suitable assay techniques well known in the art include Western Blotting and Radial Immunodiffusion Assay, e.g. as described by Hudson et al., 1989.

The oligonucleotide probe for use in the identification of suitable parent  $\alpha$ -amylases on the basis of probe hybridization [criterion b) above] may suitably be  
20 prepared on the basis of the full or partial amino acid or nucleotide sequence shown in SEQ ID No. 1 and 2 (encoding or constituting, respectively, the  $\alpha$ -amylase obtainable from *Bacillus* strain NCIB 12289). Suitable conditions for testing hybridization involve presoaking in 5xSSC and prehybridizing for 1h at  $\sim 40^{\circ}\text{C}$  in a solution of 20% formamide, 5xDenhardt's solution, 50mM sodium  
25 phosphate, pH 6.8, and 50 $\mu\text{g}$  of denatured sonicated calf thymus DNA, followed by hybridization in the same solution supplemented with 100 $\mu\text{M}$  ATP for 18h at  $\sim 40^{\circ}\text{C}$ , or other methods described by e.g. Sambrook et al., 1989.

### Influence of mutations on particular properties

From the results obtained by the present inventors it appears that changes in a particular property, e.g. thermal stability or oxidation stability, exhibited by a variant relative to the parent  $\alpha$ -amylase can to a considerable extent be correlated with the type of, and positioning of, mutation(s) (amino acid substitutions, deletions or insertions) in the variant. It is to be understood, however, that the observation that a particular mutation or pattern of mutations leads to changes in a given property in no way excludes the possibility that the mutation(s) in question can also influence other properties.

- 10 Oxidation stability: With respect to increasing the oxidation stability of an  $\alpha$ -amylase variant relative to its parent  $\alpha$ -amylase, it appears to be particularly desirable that at least one, and preferably multiple, oxidizable amino acid residue(s) of the parent has/have been deleted or replaced (i.e. substituted by) a different amino acid residue which is less susceptible to oxidation than the original oxidizable amino acid residue.

Particularly relevant oxidizable amino acid residues in this connection are methionine, tryptophan, cysteine and tyrosine, especially methionine, and deletion or substitution [e.g. by threonine (T), or by one of the other amino acids listed above] of one or more methionine residues in positions M9, M10, M105, M202, M208, M261, M309, M382, M430 and M440 of the amino acid sequence shown in SEQ ID No. 1 (or in equivalent positions in another parent  $\alpha$ -amylase meeting one of the other criteria mentioned above) appear to be particularly effective with respect to increasing the oxidation stability. In this connection, the term "equivalent positions" denotes positions which, on the basis of an alignment of the amino acid sequence of the parent  $\alpha$ -amylase in question with the sequence shown in SEQ ID No. 1 so as to achieve juxtapositioning of amino acid residues/regions which are common to both, correspond to the above-mentioned positions in the sequence shown in SEQ ID No. 1.

Particularly interesting mutations in connection with modification of oxidation stability are the following methionine substitutions in the amino acid sequence shown in SEQ ID No. 1 (or their equivalents): M9L; M10L; M202A,R,N,D,Q,E,G,H,I,L,K,F,P,S,T,W,Y,V; M261L; M309L; M382L; M430L;  
 5 M440L.

Thermal stability: With respect to increasing the thermal stability of an  $\alpha$ -amylase variant relative to its parent  $\alpha$ -amylase, it appears to be particularly desirable to delete at least one, and preferably two or even three, of the following amino acid residues in the amino acid sequence shown in SEQ ID No. 1 (or their equivalents):  
 10 F180, R181, G182, T183, G184 or K185; particularly interesting pairwise deletions of this type are the deletions: R181\* + G182\*; and T183\* + G184\* (or their equivalents).

Other mutations which appear to be of importance in connection with thermal stability are the following substitutions in the amino acid sequence shown in SEQ  
 15 ID No. 1 (or their equivalents): P260E; R124P; M105F,I,L,V; M208F,W,Y; L217I; V206I,L,F.

Ca<sup>2+</sup> dependency: With respect to decreasing the Ca<sup>2+</sup> dependency of an  $\alpha$ -amylase variant relative to its parent  $\alpha$ -amylase, it appears to be particularly desirable to incorporate one of the following substitutions in the amino acid  
 20 sequence shown in SEQ ID No. 1 (or its equivalent): Y243F; K108R; K179R; K239R; K242R; K269R; D163N; D188N; D192N; D199N; D205N; D207N; D209N; E190Q; E194Q; N106D.

In the Experimental section below, the construction of a number of variants according to the invention is described.

25  $\alpha$ -Amylase variants of the invention will, apart from having one or more improved properties as discussed above, preferably be such that they have a higher starch hydrolysis velocity at low substrate concentrations than the parent  $\alpha$ -amylase.

Alternatively, an  $\alpha$ -amylase variant of the invention will preferably be one which has a higher  $V_{max}$  and/or a lower  $K_m$  than the parent  $\alpha$ -amylase when tested under the same conditions. In the case of a hybrid  $\alpha$ -amylase, the "parent  $\alpha$ -amylase" to be used for the comparison should be the one of the constituent  
5 enzymes having the best performance.

The  $V_{max}$ ,  $K_m$  and  $V$  may be determined by well-known procedures.

#### Methods of preparing $\alpha$ -amylase variants

Several methods for introducing mutations into genes are known in the art. After a brief discussion of the cloning of  $\alpha$ -amylase-encoding DNA sequences, methods  
10 for generating mutations at specific sites within the  $\alpha$ -amylase-encoding sequence will be discussed.

#### Cloning a DNA sequence encoding an $\alpha$ -amylase

The DNA sequence encoding a parent  $\alpha$ -amylase may be isolated from any cell or microorganism producing the  $\alpha$ -amylase in question, using various methods  
15 well known in the art. First, a genomic DNA and/or cDNA library should be constructed using chromosomal DNA or messenger RNA from the organism that produces the  $\alpha$ -amylase to be studied. Then, if the amino acid sequence of the  $\alpha$ -amylase is known, homologous, labelled oligonucleotide probes may be synthesized and used to identify  $\alpha$ -amylase-encoding clones from a genomic  
20 library prepared from the organism in question. Alternatively, a labelled oligonucleotide probe containing sequences homologous to a known  $\alpha$ -amylase gene could be used as a probe to identify  $\alpha$ -amylase-encoding clones, using hybridization and washing conditions of lower stringency.

Yet another method for identifying  $\alpha$ -amylase-encoding clones would involve  
25 inserting fragments of genomic DNA into an expression vector, such as a plasmid, transforming  $\alpha$ -amylase-negative bacteria with the resulting genomic DNA library, and then plating the transformed bacteria onto agar containing a



substrate for  $\alpha$ -amylase, thereby allowing clones expressing the  $\alpha$ -amylase to be identified.

Alternatively, the DNA sequence encoding the enzyme may be prepared synthetically by established standard methods, e.g. the phosphoramidite method described by S.L. Beaucage and M.H. Caruthers (1981) or the method described by Matthes et al. (1984). In the phosphoramidite method, oligonucleotides are synthesized, e.g. in an automatic DNA synthesizer, purified, annealed, ligated and cloned in appropriate vectors.

Finally, the DNA sequence may be of mixed genomic and synthetic origin, mixed synthetic and cDNA origin or mixed genomic and cDNA origin, prepared by ligating fragments of synthetic, genomic or cDNA origin (as appropriate, the fragments corresponding to various parts of the entire DNA sequence), in accordance with standard techniques. The DNA sequence may also be prepared by polymerase chain reaction (PCR) using specific primers, for instance as described in US 4,683,202 or R.K. Saiki et al. (1988).

#### Site-directed mutagenesis

Once an  $\alpha$ -amylase-encoding DNA sequence has been isolated, and desirable sites for mutation identified, mutations may be introduced using synthetic oligonucleotides. These oligonucleotides contain nucleotide sequences flanking the desired mutation sites; mutant nucleotides are inserted during oligonucleotide synthesis. In a specific method, a single-stranded gap of DNA, bridging the  $\alpha$ -amylase-encoding sequence, is created in a vector carrying the  $\alpha$ -amylase gene. Then the synthetic nucleotide, bearing the desired mutation, is annealed to a homologous portion of the single-stranded DNA. The remaining gap is then filled in with DNA polymerase I (Klenow fragment) and the construct is ligated using T4 ligase. A specific example of this method is described in Morinaga et al. (1984). US 4,760,025 discloses the introduction of oligonucleotides encoding multiple mutations by performing minor alterations of the cassette. However, an even greater variety of mutations can be introduced at any one time by the

Morinaga method, because a multitude of oligonucleotides, of various lengths, can be introduced.

Another method of introducing mutations into  $\alpha$ -amylase-encoding DNA sequences is described in Nelson and Long (1989). It involves the 3-step generation of a PCR fragment containing the desired mutation introduced by using a chemically synthesized DNA strand as one of the primers in the PCR reactions. From the PCR-generated fragment, a DNA fragment carrying the mutation may be isolated by cleavage with restriction endonucleases and reinserted into an expression plasmid.

#### 10 Random mutagenesis

Random mutagenesis is suitably performed either as localized or region-specific random mutagenesis in at least three parts of the gene translating to the amino acid sequence shown in SEQ ID No. 1, or within the whole gene. For region-specific random mutagenesis with a view to improving the thermal stability, the following codon positions, in particular, may appropriately be targetted (using one-letter amino acid abbreviations):

120-140 = VEVNRSNRNQETSGEYAIEAW

178-187 = YKFRGTGKAW

264-275 = VAEFWKNDLGAIEN

20 With a view to achieving reduced  $\text{Ca}^{2+}$  dependency, the following codon positions, in particular, may appropriately be targetted:

178-209 = YKFRGTGKAWDWEVDTENGNYDYLMYADVDM

237-246 = AVKHIKYSFT

The random mutagenesis of a DNA sequence encoding a parent  $\alpha$ -amylase to be performed in accordance with step a) of the above-described method of the

invention may conveniently be performed by use of any method known in the art.

For instance, the random mutagenesis may be performed by use of a suitable physical or chemical mutagenizing agent, by use of a suitable oligonucleotide, or by subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, 5 the random mutagenesis may be performed by use of any combination of these mutagenizing agents.

The mutagenizing agent may, e.g., be one which induces transitions, transversions, inversions, scrambling, deletions, and/or insertions.

Examples of a physical or chemical mutagenizing agent suitable for the present 10 purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues.

When such agents are used, the mutagenesis is typically performed by incubating the DNA sequence encoding the parent enzyme to be mutagenized in the 15 presence of the mutagenizing agent of choice under suitable conditions for the mutagenesis to take place, and selecting for mutated DNA having the desired properties.

When the mutagenesis is performed by the use of an oligonucleotide, the oligonucleotide may be doped or spiked with the three non-parent nucleotides 20 during the synthesis of the oligonucleotide at the positions which are to be changed. The doping or spiking may be done so that codons for unwanted amino acids are avoided. The doped or spiked oligonucleotide can be incorporated into the DNA encoding the amylolytic enzyme by any published technique, using e.g. PCR, LCR or any DNA polymerase and ligase.

25 When PCR-generated mutagenesis is used, either a chemically treated or non-treated gene encoding a parent  $\alpha$ -amylase enzyme is subjected to PCR under

conditions that increase the misincorporation of nucleotides (Deshler 1992; Leung et al., Technique, Vol.1, 1989, pp. 11-15).

A mutator strain of *E. coli* (Fowler et al., Molec. Gen. Genet., 133, 1974, pp. 179-191), *S. cerevisiae* or any other microbial organism may be used for the random mutagenesis of the DNA encoding the amylolytic enzyme by e.g. transforming a plasmid containing the parent enzyme into the mutator strain, growing the mutator strain with the plasmid and isolating the mutated plasmid from the mutator strain. The mutated plasmid may subsequently be transformed into the expression organism.

10 The DNA sequence to be mutagenized may conveniently be present in a genomic or cDNA library prepared from an organism expressing the parent amylolytic enzyme. Alternatively, the DNA sequence may be present on a suitable vector such as a plasmid or a bacteriophage, which as such may be incubated with or otherwise exposed to the mutagenizing agent. The DNA to be mutagenized may  
15 also be present in a host cell either by being integrated in the genome of said cell or by being present on a vector harboured in the cell. Finally, the DNA to be mutagenized may be in isolated form. It will be understood that the DNA sequence to be subjected to random mutagenesis is preferably a cDNA or a genomic DNA sequence.

20 In some cases it may be convenient to amplify the mutated DNA sequence prior to the expression step (b) or the screening step (c) being performed. Such amplification may be performed in accordance with methods known in the art, the presently preferred method being PCR-generated amplification using oligonucleotide primers prepared on the basis of the DNA or amino acid sequence  
25 of the parent enzyme.

Subsequent to the incubation with or exposure to the mutagenizing agent, the mutated DNA is expressed by culturing a suitable host cell carrying the DNA sequence under conditions allowing expression to take place. The host cell used

for this purpose may be one which has been transformed with the mutated DNA sequence, optionally present on a vector, or one which was carried the DNA sequence encoding the parent enzyme during the mutagenesis treatment. Examples of suitable host cells are the following: grampositive bacteria such as  
5 *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, *Streptomyces lividans* or *Streptomyces murinus*; and gramnegative bacteria such as *E.coli*.

- 10 The mutated DNA sequence may further comprise a DNA sequence encoding functions permitting expression of the mutated DNA sequence.

Localized random mutagenesis: the random mutagenesis may advantageously be located to a part of the parent  $\alpha$ -amylase in question. This may, e.g., be advantageous when certain regions of the enzyme have been identified to be of  
15 particular importance for a given property of the enzyme, and when modified are expected to result in a variant having improved properties. Such regions may normally be identified when the tertiary structure of the parent enzyme has been elucidated and related to the function of the enzyme.

The localized random mutagenesis is conveniently performed by use of PCR-  
20 generated mutagenesis techniques as described above or any other suitable technique known in the art.

Alternatively, the DNA sequence encoding the part of the DNA sequence to be modified may be isolated, e.g. by being inserted into a suitable vector, and said part may subsequently be subjected to mutagenesis by use of any of the  
25 mutagenesis methods discussed above.

With respect to the screening step in the above-mentioned method of the invention, this may conveniently be performed by use of a filter assay based on the following principle:

A microorganism capable of expressing the mutated amylolytic enzyme of interest is incubated on a suitable medium and under suitable conditions for the enzyme to be secreted, the medium being provided with a double filter comprising a first protein-binding filter and on top of that a second filter exhibiting a low protein binding capability. The microorganism is located on the second filter. Subsequent to the incubation, the first filter comprising enzymes secreted from the microorganisms is separated from the second filter comprising the microorganisms. The first filter is subjected to screening for the desired enzymatic activity and the corresponding microbial colonies present on the second filter are identified.

The filter used for binding the enzymatic activity may be any protein binding filter e.g. nylon or nitrocellulose. The topfilter carrying the colonies of the expression organism may be any filter that has no or low affinity for binding proteins e.g. cellulose acetate or Durapore™. The filter may be pretreated with any of the conditions to be used for screening or may be treated during the detection of enzymatic activity.

The enzymatic activity may be detected by a dye, fluorescence, precipitation, pH indicator, IR-absorbance or any other known technique for detection of enzymatic activity.

The detecting compound may be immobilized by any immobilizing agent e.g. agarose, agar, gelatine, polyacrylamide, starch, filter paper, cloth; or any combination of immobilizing agents.

$\alpha$ -Amylase activity is detected by Cibacron Red labelled amylopectin, which is immobilized on agarose. For screening for variants with increased thermal and

high-pH stability, the filter with bound  $\alpha$ -amylase variants is incubated in a buffer at pH 10.5 and 60° or 65°C for a specified time, rinsed briefly in deionized water and placed on the amylopectin-agarose matrix for activity detection. Residual activity is seen as lysis of Cibacron Red by amylopectin degradation. The  
5 conditions are chosen to be such that activity due to the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No.1 can barely be detected. Stabilized variants show, under the same conditions, increased colour intensity due to increased liberation of Cibacron Red.

For screening for variants with an activity optimum at a lower temperature and/or  
10 over a broader temperature range, the filter with bound variants is placed directly on the amylopectin-Cibacron Red substrate plate and incubated at the desired temperature (e.g. 4°C, 10°C or 30°C) for a specified time. After this time activity due to the  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No.1 can barely be detected, whereas variants with optimum activity at a lower  
15 temperature will show increase amylopectin lysis. Prior to incubation onto the amylopectin matrix, incubation in all kinds of desired media - e.g. solutions containing  $\text{Ca}^{2+}$ , detergents, EDTA or other relevant additives - can be carried out in order to screen for changed dependency or for reaction of the variants in question with such additives.

## 20 Methods of preparing hybrid $\alpha$ -amylases

As an alternative to site-specific mutagenesis,  $\alpha$ -amylase variants which are hybrids of at least two constituent  $\alpha$ -amylases may be prepared by combining the relevant parts of the respective genes in question.

Naturally occurring enzymes may be genetically modified by random or site  
25 directed mutagenesis as described above. Alternatively, part of one enzyme may be replaced by a part of another to obtain a chimeric enzyme. This replacement can be achieved either by conventional *in vitro* gene splicing techniques or by *in vivo* recombination or by combinations of both techniques. When using conventional *in vitro* gene splicing techniques, a desired portion of the  $\alpha$ -amylase

gene coding sequence may be deleted using appropriate site-specific restriction enzymes; the deleted portion of the coding sequence may then be replaced by the insertion of a desired portion of a different  $\alpha$ -amylase coding sequence so that a chimeric nucleotide sequence encoding a new  $\alpha$ -amylase is produced.

5 Alternatively,  $\alpha$ -amylase genes may be fused, e.g. by use of the PCR overlay extension method described by Higuchi et al. 1988.

The *in vivo* recombination techniques depend on the fact that different DNA segments with highly homologous regions (identity of DNA sequence) may recombine, i.e. break and exchange DNA, and establish new bonds in the

10 homologous regions. Accordingly, when the coding sequences for two different but homologous amylase enzymes are used to transform a host cell, recombination of homologous sequences *in vivo* will result in the production of chimeric gene sequences. Translation of these coding sequences by the host cell will result in production of a chimeric amylase gene product. Specific *in vivo*

15 recombination techniques are described in US 5,093,257 and EP 252 666.

Alternatively, the hybrid enzyme may be synthesized by standard chemical methods known in the art. For example, see Hunkapiller et al. (1984). Accordingly, peptides having the appropriate amino acid sequences may be synthesized in whole or in part and joined to form hybrid enzymes (variants) of the

20 invention.

#### Expression of $\alpha$ -amylase variants

According to the invention, a mutated  $\alpha$ -amylase-encoding DNA sequence produced by methods described above, or by any alternative methods known in the art, can be expressed, in enzyme form, using an expression vector which

25 typically includes control sequences encoding a promoter, operator, ribosome binding site, translation initiation signal, and, optionally, a repressor gene or various activator genes.



The recombinant expression vector carrying the DNA sequence encoding an  $\alpha$ -amylase variant of the invention encoding may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, 5 the vector may be an autonomously replicating vector, i.e. a vector which exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid, a bacteriophage or an extrachromosomal element, minichromosome or an artificial chromosome. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host 10 cell genome and replicated together with the chromosome(s) into which it has been integrated.

In the vector, the DNA sequence should be operably connected to a suitable promoter sequence. The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes 15 encoding proteins either homologous or heterologous to the host cell. Examples of suitable promoters for directing the transcription of the DNA sequence encoding an  $\alpha$ -amylase variant of the invention, especially in a bacterial host, are the promoter of the *lac* operon of *E.coli*, the *Streptomyces coelicolor* agarase gene *dagA* promoters, the promoters of the *Bacillus licheniformis*  $\alpha$ -amylase gene 20 (*amyL*), the promoters of the *Bacillus stearothermophilus* maltogenic amylase gene (*amyM*), the promoters of the *Bacillus Amyloliquefaciens*  $\alpha$ -amylase (*amyQ*), the promoters of the *Bacillus subtilis* xylA and xylB genes etc. For transcription in a fungal host, examples of useful promoters are those derived from the gene encoding *A. oryzae* TAKA amylase, *Rhizomucor miehei* aspartic proteinase, *A. niger* neutral  $\alpha$ -amylase, *A. niger* acid stable  $\alpha$ -amylase, *A. niger* glucoamylase, 25 *Rhizomucor miehei* lipase, *A. oryzae* alkaline protease, *A. oryzae* triose phosphate isomerase or *A. nidulans* acetamidase.

The expression vector of the invention may also comprise a suitable transcription terminator and, in eukaryotes, polyadenylation sequences operably connected to 30 the DNA sequence encoding the  $\alpha$ -amylase variant of the invention. Termination

and polyadenylation sequences may suitably be derived from the same sources as the promoter.

The vector may further comprise a DNA sequence enabling the vector to replicate in the host cell in question. Examples of such sequences are the origins of replication of plasmids pUC19, pACYC177, pUB110, pE194, pAMB1 and pIJ702.

The vector may also comprise a selectable marker, e.g. a gene the product of which complements a defect in the host cell, such as the *dal* genes from *B. subtilis* or *B. licheniformis*, or one which confers antibiotic resistance such as ampicillin, kanamycin, chloramphenicol or tetracycline resistance. Furthermore, the vector may comprise *Aspergillus* selection markers such as *amdS*, *argB*, *niaD* and *sC*, a marker giving rise to hygromycin resistance, or the selection may be accomplished by co-transformation, e.g. as described in WO 91/17243.

While intracellular expression may be advantageous in some respects, e.g. when using certain bacteria as host cells, it is generally preferred that the expression is extracellular.

The procedures used to ligate the DNA construct of the invention encoding an  $\alpha$ -amylase variant, the promoter, terminator and other elements, respectively, and to insert them into suitable vectors containing the information necessary for replication, are well known to persons skilled in the art (cf., for instance, Sambrook et al. (1989)).

The cell of the invention, either comprising a DNA construct or an expression vector of the invention as defined above, is advantageously used as a host cell in the recombinant production of an  $\alpha$ -amylase variant of the invention. The cell may be transformed with the DNA construct of the invention encoding the variant, conveniently by integrating the DNA construct (in one or more copies) in the host chromosome. This integration is generally considered to be an advantage as the DNA sequence is more likely to be stably maintained in the cell.

Integration of the DNA constructs into the host chromosome may be performed according to conventional methods, e.g. by homologous or heterologous recombination. Alternatively, the cell may be transformed with an expression vector as described above in connection with the different types of host cells.

- 5 The cell of the invention may be a cell of a higher organism such as a mammal or an insect, but is preferably a microbial cell, e.g. a bacterial or a fungal (including yeast) cell.

Examples of suitable bacteria are grampositive bacteria such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*,  
10 *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus megaterium*, *Bacillus thuringiensis*, or *Streptomyces lividans* or *Streptomyces murinus*, or gramnegative bacteria such as *E.coli*. The transformation of the bacteria may, for instance, be effected by protoplast transformation or by using competent cells in a manner known *per se*.

- 15 The yeast organism may favourably be selected from a species of *Saccharomyces* or *Schizosaccharomyces*, e.g. *Saccharomyces cerevisiae*. The filamentous fungus may advantageously belong to a species of *Aspergillus*, e.g. *Aspergillus oryzae* or *Aspergillus niger*. Fungal cells may be transformed by a process involving protoplast formation and transformation of the protoplasts followed by regen-  
20 eration of the cell wall in a manner known *per se*. A suitable procedure for transformation of *Aspergillus* host cells is described in EP 238 023.

In a yet further aspect, the present invention relates to a method of producing an  $\alpha$ -amylase variant of the invention, which method comprises cultivating a host cell as described above under conditions conducive to the production of the  
25 variant and recovering the variant from the cells and/or culture medium.

The medium used to cultivate the cells may be any conventional medium suitable for growing the host cell in question and obtaining expression of the  $\alpha$ -amylase

variant of the invention. Suitable media are available from commercial suppliers or may be prepared according to published recipes (e.g. as described in catalogues of the American Type Culture Collection).

The  $\alpha$ -amylase variant secreted from the host cells may conveniently be recovered from the culture medium by well-known procedures, including separating the cells from the medium by centrifugation or filtration, and precipitating proteinaceous components of the medium by means of a salt such as ammonium sulphate, followed by the use of chromatographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

#### 10 Detergent Additive and Composition for Dishwashing and Washing

Due to the improved washing and/or dishwashing performance which will often be a consequence of improvements in properties as discussed above, numerous  $\alpha$ -amylase variants (including hybrids) of the invention are particularly well suited for incorporation into detergent compositions, e.g. detergent compositions intended for performance in the range of pH 7-13, particularly the range of pH 8-11.

According to the invention, the  $\alpha$ -amylase variant may be added as a component of a detergent composition. As such, it may be included in the detergent composition in the form of a detergent additive. The detergent composition as well as the detergent additive may additionally comprise one or more other enzymes conventionally used in detergents, such as proteases, lipases, amylolytic enzymes, oxidases (including peroxidases), or cellulases.

It has been found that substantial improvements in washing and/or dishwashing performance may be obtained when  $\alpha$ -amylase is combined with another amylolytic enzyme, such as a pullulanase, an iso-amylase, a beta-amylase, an amyloglucosidase or a CTGase. Examples of commercially available amylolytic enzymes suitable for the given purpose are AMG®, Novamyl® and Promozyme®, all available from Novo Nordisk A/S.

Accordingly, in a particular embodiment the invention relates to a detergent additive comprising an  $\alpha$ -amylase variant of the invention in combination with at least one other amylolytic enzyme (e.g. chosen amongst those mentioned above).

In a specific aspect, the invention provides a detergent additive. The enzymes  
5 may be included in a detergent composition by adding separate additives containing one or more enzymes, or by adding a combined additive comprising all of these enzymes. A detergent additive of the invention, i.e. a separated additive or a combined additive, can be formulated, e.g., as a granulate, liquid, slurry, etc. Preferred detergent additive formulations are granulates (in particular  
10 non-dusting granulates), liquids (in particular stabilized liquids), slurries or protected enzymes.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and US 4,661,452, and may optionally be coated by methods known in the art. The detergent enzymes may be mixed before or after granulation.

15 Liquid enzyme preparations may, for instance, be stabilized by adding a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238 216.

20 In a still further aspect, the invention relates to a detergent composition comprising an  $\alpha$ -amylase variant (including hybrid) of the invention.

The detergent composition of the invention may be in any convenient form, e.g. as powder, granules or liquid. A liquid detergent may be aqueous, typically containing up to 90% of water and 0-20% of organic solvent, or non-aqueous,  
25 e.g. as described in EP Patent 120,659.

### Detergent compositions

According to the invention, the  $\alpha$ -amylase may typically be a component of a detergent composition. As such, it may be included in the detergent composition in the form of a non-dusting granulate, a stabilized liquid, or a protected enzyme.

5 Non-dusting granulates may be produced, e.g. as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molar weights of 1000 to 20000, ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated  
10 fatty alcohols in which the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids. Examples of film-forming coating materials suitable for application by fluid bed techniques are given in patent GB 1483591. Liquid enzyme preparations may, for instance, be stabilized by adding  
15 a polyol such as propylene glycol, a sugar or sugar alcohol, lactic acid or boric acid according to established methods. Other enzyme stabilizers are well known in the art. Protected enzymes may be prepared according to the method disclosed in EP 238,216.

The detergent composition of the invention may be in any convenient form, e.g.  
20 as powder, granules, paste or liquid. A liquid detergent may be aqueous, typically containing up to 70% of water and 0-30% of organic solvent, or nonaqueous.

The detergent composition comprises one or more surfactants, each of which may be anionic, nonionic, cationic, or zwitterionic. The detergent will usually contain 0-50% of anionic surfactant such as linear alkylbenzenesulfonate (LAS),  
25 alpha-olefinsulfonate (AOS), alkyl sulfate (fatty alcohol sulfate) (AS), alcohol ethoxysulfate (AEOS or AES), secondary alkanesulfonates (SAS), alpha-sulfo fatty acid methyl esters, alkyl- or alkenylsuccinic acid or soap. It may also contain 0-40% of nonionic surfactant such as alcohol ethoxylate (AEO or AE), carboxylated alcohol ethoxylates, nonylphenol ethoxylate, alkylpolyglycoside,  
30 alkyldimethylamineoxide, ethoxylated fatty acid monoethanolamide, fatty acid

monoethanolamide, or polyhydroxy alkyl fatty acid amide (e.g. as described in WO 92/06154).

The detergent composition may additionally comprise one or more other enzymes, such as lipase, cutinase, protease, cellulase, peroxidase, e.g., laccase.

- 5 The detergent may contain 1-65% of a detergent builder or complexing agent such as zeolite, diphosphate, triphosphate, phosphonate, citrate, nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTMPA), alkyl- or alkenylsuccinic acid, soluble silicates or layered silicates (e.g. SKS-6 from Hoechst). The detergent may also be unbuilt,  
10 i.e. essentially free of detergent builder.

The detergent may comprise one or more polymers. Examples are carboxymethylcellulose (CMC), poly(vinylpyrrolidone) (PVP), polyethyleneglycol (PEG), poly(vinyl alcohol) (PVA), polycarboxylates such as polyacrylates, maleic/acrylic acid copolymers and lauryl methacrylate/acrylic acid copolymers.

- 15 The detergent may contain a bleaching system which may comprise a  $H_2O_2$  source such as perborate or percarbonate which may be combined with a peracid-forming bleach activator such as tetraacetythylenediamine (TAED) or nonanoyloxybenzenesulfonate (NOBS). Alternatively, the bleaching system may comprise peroxy acids of e.g. the amide, imide, or sulfone type.
- 20 The enzymes of the detergent composition of the invention may be stabilized using conventional stabilizing agents, e.g. a polyol such as propylene glycol or glycerol, a sugar or sugar alcohol, lactic acid, boric acid, or a boric acid derivative as e.g. an aromatic borate ester, and the composition may be formulated as described in e.g. WO 92/19709 and WO 92/19708.
- 25 The detergent may also contain other conventional detergent ingredients such as e.g. fabric conditioners including clays, foam boosters, suds suppressors, anti-

corrosion agents, soil-suspending agents, anti-soil redeposition agents, dyes, bactericides, optical brighteners, or perfume.

The pH (measured in aqueous solution at use concentration) will usually be neutral or alkaline, e.g. 7-11.

5 Particular forms of detergent compositions within the scope of the invention include:

1) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

10	Linear alkylbenzenesulfonate (calculated as acid)	7 - 12%
	Alcohol ethoxysulfate (e.g. C <sub>12-18</sub> alcohol, 1-2 EO) or alkyl sulfate (e.g. C <sub>16-18</sub> )	1 - 4%
	Alcohol ethoxylate (e.g. C <sub>14-15</sub> alcohol, 7 EO)	5 - 9%
15	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	14 - 20%
	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	2 - 6%
	Zeolite (as NaA1SiO <sub>4</sub> )	15 - 22%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0 - 6%
20	Sodium citrate/citric acid (as C <sub>6</sub> H <sub>5</sub> Na <sub>3</sub> O <sub>7</sub> /C <sub>6</sub> H <sub>8</sub> O <sub>7</sub> )	0 - 15%
	Sodium perborate (as NaBO <sub>3</sub> ·H <sub>2</sub> O)	11 - 18%
	TAED	2 - 6%
	Carboxymethylcellulose	0 - 2%
25	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. suds suppressors, perfume, optical brightener, photobleach)	0 - 5%



2) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

	Linear alkylbenzenesulfonate (calculated as acid)	6 - 11 %
5	Alcohol ethoxysulfate (e.g. C <sub>12-18</sub> alcohol, 1-2 EO or alkyl sulfate (e.g. C <sub>16-18</sub> ))	1 - 3 %
	Alcohol ethoxylate (e.g. C <sub>14-15</sub> alcohol, 7 EO)	5 - 9 %
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	15 - 21 %
10	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	1 - 4 %
	Zeolite (as NaA1SiO <sub>4</sub> )	24 - 34 %
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	4 - 10 %
	Sodium citrate/citric acid (as C <sub>6</sub> H <sub>5</sub> Na <sub>3</sub> O <sub>7</sub> /C <sub>6</sub> H <sub>8</sub> O <sub>7</sub> )	0 - 15 %
15	Carboxymethylcellulose	0 - 2 %
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 6 %
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1 %
20	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5 %

3) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

25	Linear alkylbenzenesulfonate (calculated as acid)	5 - 9 %
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO)	7 - 14 %
	Soap as fatty acid (e.g. C <sub>16-22</sub> fatty acid)	1 - 3 %
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	10 - 17 %
30	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	3 - 9 %

	Zeolite (as NaA1SiO <sub>4</sub> )	23 - 33%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0 - 4%
	Sodium perborate (as NaBO <sub>3</sub> ·H <sub>2</sub> O)	8 - 16%
	TAED	2 - 8%
5	Phosphonate (e.g. EDTMPA)	0 - 1%
	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	0 - 3%
10	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. suds suppressors, perfume, optical brightener)	0 - 5%

4) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

15	Linear alkylbenzenesulfonate (calculated as acid)	8 - 12%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO)	10 - 25%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	14 - 22%
20	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	1 - 5%
	Zeolite (as NaA1SiO <sub>4</sub> )	25 - 35%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	0 - 10%
	Carboxymethylcellulose	0 - 2%
25	Polymers (e.g. maleic/acrylic acid copolymer, PVP, PEG)	1 - 3%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

30 5) An aqueous liquid detergent composition comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	15	- 21%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO or C <sub>12-15</sub> alcohol, 5 EO)	12	- 18%
	Soap as fatty acid (e.g. oleic acid)	3	- 13%
	Alkenylsuccinic acid (C <sub>12-14</sub> )	0	- 13%
	Aminoethanol	8	- 18%
10	Citric acid	2	- 8%
	Phosphonate	0	- 3%
	Polymers (e.g. PVP, PEG)	0	- 3%
	Borate (as B <sub>4</sub> O <sub>7</sub> )	0	- 2%
	Ethanol	0	- 3%
15	Propylene glycol	8	- 14%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brightener)	0	- 5%

6) An aqueous structured liquid detergent composition comprising

5	Linear alkylbenzenesulfonate (calculated as acid)	15 - 21%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO, or C <sub>12-15</sub> alcohol, 5 EO)	3 - 9%
	Soap as fatty acid (e.g. oleic acid)	3 - 10%
	Zeolite (as NaA1SiO <sub>4</sub> )	14 - 22%
	Potassium citrate	9 - 18%
10	Borate (as B <sub>4</sub> O <sub>7</sub> )	0 - 2%
	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. PEG, PVP)	0 - 3%
	Anchoring polymers such as, e.g., lauryl methacrylate/acrylic acid copolymer; molar ratio 25:1; MW 3800	0 - 3%
	Glycerol	0 - 5%
15	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. dispersants, suds suppressors, perfume, optical brighteners)	0 - 5%

7) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

25	Fatty alcohol sulfate	5 - 10%
	Ethoxylated fatty acid monoethanolamide	3 - 9%
	Soap as fatty acid	0 - 3%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	5 - 10%
	Soluble silicate (as Na <sub>2</sub> O, 2SiO <sub>2</sub> )	1 - 4%
30	Zeolite (as NaA1SiO <sub>4</sub> )	20 - 40%
	Sodium sulfate (as Na <sub>2</sub> SO <sub>4</sub> )	2 - 8%
	Sodium perborate (as NaBO <sub>3</sub> ·H <sub>2</sub> O)	12 - 18%
	TAED	2 - 7%
	Polymers (e.g. maleic/acrylic acid copolymer, PEG)	1 - 5%

Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
Minor ingredients (e.g. optical brightener, suds suppressors, perfume)	0 - 5%

5 8) A detergent composition formulated as a granulate comprising

	Linear alkylbenzenesulfonate (calculated as acid)	8 - 14%
	Ethoxylated fatty acid monoethanolamide	5 - 11%
	Soap as fatty acid	0 - 3%
10	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	4 - 10%
	Soluble silicate (as $\text{Na}_2\text{O}, 2\text{SiO}_2$ )	1 - 4%
	Zeolite (as $\text{NaA1SiO}_4$ )	30 - 50%
	Sodium sulfate (as $\text{Na}_2\text{SO}_4$ )	3 - 11%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$ )	5 - 12%
15	Polymers (e.g. PVP, maleic/acrylic acid copolymer, PEG)	1 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
20	Minor ingredients (e.g. suds suppressors, perfume)	0 - 5%

9) A detergent composition formulated as a granulate comprising

	Linear alkylbenzenesulfonate (calculated as acid)	6 - 12%
	Nonionic surfactant	1 - 4%
25	Soap as fatty acid	2 - 6%
	Sodium carbonate (as $\text{Na}_2\text{CO}_3$ )	14 - 22%
	Zeolite (as $\text{NaA1SiO}_4$ )	18 - 32%
	Sodium sulfate (as $\text{Na}_2\text{SO}_4$ )	5 - 20%
	Sodium citrate (as $\text{C}_6\text{H}_5\text{Na}_3\text{O}_7$ )	3 - 8%
30	Sodium perborate (as $\text{NaBO}_3 \cdot \text{H}_2\text{O}$ )	4 - 9%

5	Bleach activator (e.g. NOBS or TAED)	1 - 5%
	Carboxymethylcellulose	0 - 2%
	Polymers (e.g. polycarboxylate or PEG)	1 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. optical brightener, perfume)	0 - 5%

10) An aqueous liquid detergent composition comprising

10	Linear alkylbenzenesulfonate (calculated as acid)	15 - 23%
	Alcohol ethoxysulfate (e.g. C <sub>12-15</sub> alcohol, 2-3 EO)	8 - 15%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO, or C <sub>12-15</sub> alcohol, 5 EO)	3 - 9%
15	Soap as fatty acid (e.g. lauric acid)	0 - 3%
	Aminoethanol	1 - 5%
	Sodium citrate	5 - 10%
	Hydrotrope (e.g. sodium toluenesulfonate)	2 - 6%
20	Borate (as B <sub>4</sub> O <sub>7</sub> )	0 - 2%
	Carboxymethylcellulose	0 - 1%
	Ethanol	1 - 3%
	Propylene glycol	2 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
25	Minor ingredients (e.g. polymers, dispersants, perfume, optical brighteners)	0 - 5%

11) An aqueous liquid detergent composition comprising

30	Linear alkylbenzenesulfonate (calculated as acid)	20 - 32%
	Alcohol ethoxylate (e.g. C <sub>12-15</sub> alcohol, 7 EO, or C <sub>12-15</sub> alcohol, 5 EO)	6 - 12%

	Aminoethanol	2 - 6%
	Citric acid	8 - 14%
	Borate (as $B_4O_7$ )	1 - 3%
5	Polymer (e.g. maleic/acrylic acid copolymer, anchoring polymer such as, e.g., lauryl methacrylate/acrylic acid copolymer)	0 - 3%
	Glycerol	3 - 8%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
10	Minor ingredients (e.g. hydrotropes, dispersants, perfume, optical brighteners)	0 - 5%

12) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

15	Anionic surfactant (linear alkylbenzene-sulfonate, alkyl sulfate, alpha-olefinsulfonate, alpha-sulfo fatty acid methyl esters, alkanesulfonates, soap)	25 - 40%
	Nonionic surfactant (e.g. alcohol ethoxylate)	1 - 10%
20	Sodium carbonate (as $Na_2CO_3$ )	8 - 25%
	Soluble silicates (as $Na_2O$ , $2SiO_2$ )	5 - 15%
	Sodium sulfate (as $Na_2SO_4$ )	0 - 5%
	Zeolite (as $NaAlSiO_4$ )	15 - 28%
	Sodium perborate (as $NaBO_3 \cdot 4H_2O$ )	0 - 20%
25	Bleach activator (TAED or NOBS)	0 - 5%
	Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
	Minor ingredients (e.g. perfume, optical brighteners)	0 - 3%

30 13) Detergent formulations as described in 1) - 12) wherein all or part of the linear alkylbenzenesulfonate is replaced by ( $C_{12}$ - $C_{18}$ ) alkyl sulfate.

14) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

5	(C <sub>12</sub> -C <sub>18</sub> ) alkyl sulfate	9	- 15%
	Alcohol ethoxylate	3	- 6%
	Polyhydroxy alkyl fatty acid amide	1	- 5%
	Zeolite (as NaA1SiO <sub>4</sub> )	10	- 20%
	Layered disilicate (e.g. SK56 from Hoechst)	10	- 20%
10	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	3	- 12%
	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	0	- 6%
	Sodium citrate	4	- 8%
	Sodium percarbonate	13	- 22%
	TAED	3	- 8%
15	Polymers (e.g. polycarboxylates and PVP =	0	- 5%
	Enzymes (calculated as pure enzyme protein)	0.0001	- 0.1%
	Minor ingredients (e.g. optical brightener, photo bleach, perfume, suds suppressors)	0	- 5%

15) A detergent composition formulated as a granulate having a bulk density of at least 600 g/l comprising

20	(C <sub>12</sub> -C <sub>18</sub> ) alkyl sulfate	4	- 8%
	Alcohol ethoxylate	11	- 15%
	Soap	1	- 4%
	Zeolite MAP or zeolite A	35	- 45%
	Sodium carbonate (as Na <sub>2</sub> CO <sub>3</sub> )	2	- 8%
25	Soluble silicate (as Na <sub>2</sub> O,2SiO <sub>2</sub> )	0	- 4%
	Sodium percarbonate	13	- 22%
	TAED	1	- 8%
	Carboxymethyl cellulose	0	- 3%



Polymers (e.g. polycarboxylates and PVP)	0 - 3%
Enzymes (calculated as pure enzyme protein)	0.0001 - 0.1%
5 Minor ingredients (e.g. optical brightener, phosphonate, perfume)	0 - 3%

16) Detergent formulations as described in 1) - 15) which contain a stabilized or encapsulated peracid, either as an additional component or as a substitute for already specified bleach systems.

17) Detergent compositions as described in 1), 3), 7), 9) and 12) wherein  
10 perborate is replaced by percarbonate.

18) Detergent compositions as described in 1), 3), 7), 9), 12), 14) and 15) which additionally contain a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", Nature 369, 1994, pp. 637-639.

15 19) Detergent composition formulated as a nonaqueous detergent liquid comprising a liquid nonionic surfactant such as, e.g., linear alkoxyated primary alcohol, a builder system (e.g. phosphate), enzyme and alkali. The detergent may also comprise anionic surfactant and/or a bleach system.

The  $\alpha$ -amylase of the invention may be incorporated in concentrations conventionally employed in detergents. It is at present contemplated that, in the  
20 detergent composition of the invention, the  $\alpha$ -amylase may be added in an amount corresponding to 0.00001-1 mg (calculated as pure enzyme protein) of  $\alpha$ -amylase per liter of wash liquor.

#### Dishwashing Composition

25 The dishwashing detergent composition comprises a surfactant which may be anionic, non-ionic, cationic, amphoteric or a mixture of these types. The

detergent will contain 0-90% of non-ionic surfactant such as low- to non-foaming ethoxylated propoxylated straight-chain alcohols.

The detergent composition may contain detergent builder salts of inorganic and/or organic types. The detergent builders may be subdivided into phosphorus-  
5 containing and non-phosphorus-containing types. The detergent composition usually contains 1-90% of detergent builders.

Examples of phosphorus-containing inorganic alkaline detergent builders, when present, include the water-soluble salts especially alkali metal pyrophosphates, orthophosphates, and polyphosphates. An example of phosphorus-containing  
10 organic alkaline detergent builder, when present, includes the water-soluble salts of phosphonates. Examples of non-phosphorus-containing inorganic builders, when present, include water-soluble alkali metal carbonates, borates and silicates as well as the various types of water-insoluble crystalline or amorphous aluminosilicates of which zeolites are the best-known representatives.

15 Examples of suitable organic builders include the alkali metal, ammonium and substituted ammonium, citrates, succinates, malonates, fatty acid sulphonates, carboxymethoxy succinates, ammonium polyacetates, carboxylates, polycarboxylates, aminopolycarboxylates, polyacetyl carboxylates and polyhydroxysulphonates. Other suitable organic builders include the higher molecular  
20 weight polymers and co-polymers known to have builder properties, for example appropriate polyacrylic acid, polymaleic and polyacrylic/polymaleic acid copolymers and their salts.

The dishwashing detergent composition may contain bleaching agents of the chlorine/bromine-type or the oxygen-type. Examples of inorganic  
25 chlorine/bromine-type bleaches are lithium, sodium or calcium hypochlorite and hypobromite as well as chlorinated trisodium phosphate. Examples of organic chlorine/bromine-type bleaches are heterocyclic N-bromo and N-chloro imides such as trichloroisocyanuric, tribromoisocyanuric, dibromoisocyanuric and

dichloroisocyanuric acids, and salts thereof with water-solubilizing cations such as potassium and sodium. Hydantoin compounds are also suitable.

The oxygen bleaches are preferred, for example in the form of an inorganic persalt, preferably with a bleach precursor or as a peroxy acid compound. Typical  
5 examples of suitable peroxy bleach compounds are alkali metal perborates, both tetrahydrates and monohydrates, alkali metal percarbonates, persilicates and perphosphates. Preferred activator materials are TAED and glycerol triacetate.

The dishwashing detergent composition of the invention may be stabilized using conventional stabilizing agents for the enzyme(s), e.g. a polyol such as  
10 e.g. propylene glycol, a sugar or a sugar alcohol, lactic acid, boric acid, or a boric acid derivative, e.g. an aromatic borate ester.

The dishwashing detergent composition of the invention may also contain other conventional detergent ingredients, e.g. deflocculant material, filler material, foam depressors, anti-corrosion agents, soil-suspending agents, sequestering agents,  
15 anti-soil redeposition agents, dehydrating agents, dyes, bactericides, fluorescers, thickeners and perfumes.

Finally, the  $\alpha$ -amylase of the invention may be used in conventional dishwashing detergents, e.g. in any of the detergents described in any of the following patent publications:

20 EP 518719, EP 518720, EP 518721, EP 516553, EP 516554,  
EP 516555, GB 2200132, DE 3741617, DE 3727911, DE 4212166,  
DE 4137470, DE 3833047, WO 93/17089, DE 4205071, WO 52/09680, WO  
93/18129, WO 93/04153, WO 92/06157, WO 92/08777, EP 429124, WO  
93/21299, US 5141664, EP 561452, EP 561446, GB 2234980,  
25 WO 93/03129, EP 481547, EP 530870, EP 533239, EP 554943,  
EP 346137, US 5112518, EP 318204, EP 318279, EP 271155,  
EP 271156, EP 346136, GB 2228945, CA 2006687, WO 93/25651,  
EP 530635, EP 414197, US 5240632.

### Textile desizing

In the textile processing industry,  $\alpha$ -amylases are traditionally used as auxiliaries in the desizing process to facilitate the removal of starch-containing size which has served as a protective coating on weft yarns during weaving.

- 5 Complete removal of the size coating after weaving is important to ensure optimum results in the subsequent processes, in which the fabric is scoured, bleached and dyed. Enzymatic starch break-down is preferred because it does not involve any harmful effect on the fibre material.

In order to reduce processing cost and increase mill throughput, the desizing  
10 processing is sometimes combined with the scouring and bleaching steps. In such cases, non-enzymatic auxiliaries such as alkali or oxidation agents are typically used to break down the starch, because traditional  $\alpha$ -amylases are not very compatible with high pH levels and bleaching agents. The non-enzymatic breakdown of the starch size does lead to some fibre damage because of the  
15 rather aggressive chemicals used.

Accordingly, it would be desirable to use  $\alpha$ -amylase enzymes having an improved resistance towards or compatible with oxidation (bleaching) agents at elevated pH, in order to retain the advantages of enzymatic size break down in a time-saving simultaneous desizing/scouring/bleaching process.

- 20 Thus,  $\alpha$ -amylase variants of the invention having improved resistance towards oxidation agents will be useful in desizing processes as described above, in particular for replacement of non-enzymatic alkali or oxidation agents used today.

The present invention is further described with reference to the appended drawing, in which Fig. 1 is a restriction map of plasmid pTVB106.

## 25 EXPERIMENTAL SECTION

Preparation of the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 from Bacillus strain NCIB 12289.

Fermentation:

The above-mentioned Bacillus strain was incubated at 26°C on a rotary shaking table (300 r.p.m.) in 500 ml baffled Erlenmeyer flasks containing 100 ml of BP-X medium + 0.1 M Carbonate buffer pH 9.0.

BP-X medium:

	Potato starch	100 g
	Ground barley	50 g
10	Soybean flour	20 g
	Sodium caseinate	10 g
	Na <sub>2</sub> HPO <sub>4</sub> ·12 H <sub>2</sub> O	9 g
	Termamyl® 60L *	0.1 g
	Pluronic®	0.1 g

15 \*) available from Novo Nordisk A/S.

The starch in the medium was liquified by slowly heating the medium from 60°C to 85°C for 30 minutes. After this the temperature of the medium was quickly raised to 95°C for 10 minutes and then cooled. Lastly the medium was sterilized by heating at 121°C for 40 minutes.

20 Purification of the  $\alpha$ -amylase

After 5 days of incubation the culture broth was filtered and concentrated using a Filtron™ ultrafiltration module with 3KD membranes and washed with deionized water until the conductivity was 1 mS/cm. The pH was adjusted to pH 5.9 with 10% (v/v) acetic acid. A S-sepharose FF column was equilibrated in EKV-buffer, pH 5.9. If not otherwise stated, the purification buffer was 100 mM boric acid, 10 mM succinic acid, 2 mM CaCl<sub>2</sub>, (EKV-buffer) adjusted to the indicated pH with NaOH.

The enzyme solution was applied to the column, the column was washed with EKV-buffer, pH 5.9, and the amylase was eluted with a linear NaCl gradient (0- > 500 mM NaCl). Amylase-containing fractions were pooled and the pH adjusted to pH 7 with 3% (w/v) NaOH.

5 A chelate agarose column was loaded with  $\text{Cu}^{++}$  and equilibrated in the following manner: 50 mM  $\text{CuSO}_4$ , pH 5 was pumped on to the column until the whole column was blue, then excess of  $\text{Cu}^{++}$  ions were removed by washing the column with 500 mM imidazole, pH 7, and finally the column was equilibrated with EKV-buffer, pH 7. The amylase pool from the S-sepharose  
10 column was applied to the  $\text{Cu}^{++}$ -loaded chelate agarose column, the column was washed with EKV-buffer, pH 7, and the enzyme was eluted with a linear gradient of imidazole (0- > 500 mM imidazole). Amylase-containing fractions were pooled and a solution of saturated ammonium sulphate was added to give a final concentration of 1M  $(\text{NH}_4)_2\text{SO}_4$  in the pool.

15 A phenyl sepharose column was equilibrated in EKV-buffer + 1M  $(\text{NH}_4)_2\text{SO}_4$ , pH 7. The amylase pool from the  $\text{Cu}^{++}$  column was applied to the hydrophobic interaction column. Binding experiments had shown that the amylase is a rather hydrophobic enzyme, and hence binds tightly to the phenyl column. Protein which did not bind as tightly to the column was washed off the column with  
20 EKV-buffer, pH 7. The amylase was step-eluted from the column with EKV-buffer + 25% (v/v) isopropanol. The amylase-containing pool was adjusted to pH 9.5 with 3% (w/v) NaOH and diluted 5 times with deionized water.

A Q-sepharose HP column was equilibrated in 20 mM Tris-HCl, pH 9.5. The amylase pool from the phenyl sepharose column was applied to the column and  
25 the column was washed with 20 mM Tris-HCl, pH 9.5. The amylase was eluted with a linear gradient of NaCl (0 -> 250 mM NaCl). The amylase peak was adjusted to pH 7 with 10% (v/v) acetic acid.

A  $\text{Cu}^{++}$ -loaded chelating sepharose FF column (loaded with  $\text{Cu}^{++}$  as described for the chelate agarose column) was equilibrated with EKV-buffer, pH 7. The amylase peak from the Q-sepharose column was applied to the column, and the column was washed thoroughly with EKV-buffer, pH 7. The amylase was eluted with a steep linear gradient of imidazole (0 -> 500 mM imidazole).

The purified amylase was purity checked by SDS-PAGE electrophoresis. The coomassie stained gel had only one band.

#### Determination of $\alpha$ -amylase activity

$\alpha$ -Amylase activity is determined by a method employing Phadebas® tablets as substrate. Phadebas tablets (Phadebas® Amylase Test, supplied by Pharmacia Diagnostic) contain a cross-linked insoluble blue-coloured starch polymer which has been mixed with bovine serum albumin and a buffer substance and tabletted.

For the determination of every single measurement one tablet is suspended in a tube containing 5 ml 50 mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM  $\text{CaCl}_2$ , pH adjusted to the value of interest with NaOH). The test is performed in a water bath at the temperature of interest. The  $\alpha$ -amylase to be tested is diluted in x ml of 50 mM Britton-Robinson buffer. 1 ml of this  $\alpha$ -amylase solution is added to the 5 ml 50 mM Britton-Robinson buffer. The starch is hydrolysed by the  $\alpha$ -amylase giving soluble blue fragments. The absorbance of the resulting blue solution, measured spectrophotometrically at 620 nm, is a function of the  $\alpha$ -amylase activity.

It is important that the measured 620 nm absorbance after 15 minutes of incubation (testing time) is in the range of 0.2 to 2.0 absorbance units at 620 nm. In this absorbance range there is linearity between activity and absorbance (Lambert-Beer law). The dilution of the enzyme must therefore be adjusted to fit this criterion.

Under a specified set of conditions (temp., pH, reaction time, buffer conditions) 1 mg of a given  $\alpha$ -amylase will hydrolyse a certain amount of substrate and a blue colour will be produced. The colour intensity is measured at 620 nm. The measured absorbance is directly proportional to the specific activity (activity/mg of pure  $\alpha$ -amylase protein) of the  $\alpha$ -amylase in question under the given set of conditions. Thus testing different  $\alpha$ -amylases of interest (including a reference  $\alpha$ -amylase, in this case the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1) under identical conditions, the specific activity of each of the  $\alpha$ -amylases at a given temperature and at a given pH can be compared directly, and the ratio of the specific activity of each of the  $\alpha$ -amylases of interest relative to the specific activity of the reference  $\alpha$ -amylase can be determined.



Mini dishwashing assay

The following mini dishwashing assay was used: A suspension of starchy material was boiled and cooled to 20°C. The cooled starch suspension was applied on small, individually identified glass plates (approx. 2 x 2 cm) and dried at a temperature in the range of 60-140°C in a drying cabinet. The individual plates were then weighed. For assay purposes, a solution of standard European-type automatic dishwashing detergent (5 g/l) having a temperature of 55°C was prepared. The detergent was allowed a dissolution time of 1 minute, after which the amylase in question was added to the detergent solution (contained in a beaker equipped with magnetic stirring) so as to give an enzyme concentration of 0.5 mg/ml. At the same time, the weighed glass plates, held in small supporting clamps, were immersed in a substantially vertical position in the amylase/detergent solution, which was then stirred for 15 minutes at 55°C. The glass plates were then removed from the amylase/detergent solution, rinsed with distilled water, dried at 60°C in a drying cabinet and re-weighed. The performance of the amylase in question [expressed as an index relative to a chosen reference  $\alpha$ -amylase (index 100) - in the present context the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1] was then determined from the difference in weight of the glass plates before and after treatment, as follows:

$$\text{Index} = \frac{\text{weight loss for plate treated with } \alpha\text{-amylase}}{\text{weight loss for plate treated with Termamyl}^{\text{®}}} \cdot 100$$

The following examples further illustrate the present invention, and they are not intended to be in any way limiting to the scope of the invention as claimed.

25 **EXAMPLE 1**Mini dishwashing test of deletion variant T183\* + G184\*

The above-described mini dishwashing test was performed at pH 10.5 with the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 and the

thermally more stable deletion variant T183\* + G184\*. The test gave the following results:

parent $\alpha$ -amylase	Index: 100
T183* + G184*	Index: 120

- 5 The results clearly illustrate the beneficial effect on dishwashing performance which may be achieved using a variant according to the invention having improved thermal stability.

## EXAMPLE 2

### Construction of variants

- 10 Description of plasmid pTVB106: The parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1 and variants thereof are expressed from a plasmid-borne gene, SF16, shown in Fig. 1. The plasmid, pTVB106, contains an origin of replication obtained from plasmid pUB110 (Gryczan et al., 1978) and the cat gene conferring resistance towards chloramphenicol. Secretion of the amylase  
15 is aided by the Termamyl™ signal sequence that is fused precisely, i.e. codon No.1 of the mature protein, to the gene encoding the parent  $\alpha$ -amylase having the nucleotide and amino acid sequence (mature protein) shown in SEQ ID No. 1. The Termamyl promoter initiates transcription of the gene.

- Plasmid pTVB106 is similar to pDN1528 (see published Danish patent application  
20 No. 1155/94). Some unique restriction sites are indicated on the plasmid map in Fig. 1, i.e. SacII, BamHI, BstEII, AflIII, DraIII, XmaI, SalI and BglII.

Construction of variant M202T: The PCR overlap extension mutagenesis method is used to construct this variant (Higuchi et al., 1988). An approximately 350 bp DNA fragment of pTVB106 is amplified in a PCR reaction A using primers #7113

and mutagenic primer #6778. In a similar PCR reaction B, an approximately 300 bp DNA fragment is amplified using primers Y296 and #6779. The complete DNA fragment spanning the mutation site (M202) from primer #7113 to primer Y296 is amplified in PCR C using these primers and purified DNA fragments from 5 reactions A and B.

PCR C DNA is digested with restriction endonucleases BstEII and AflIII, and the 480 bp fragment is ligated with plasmid pTVB106 digested with the same enzymes and transformed into a low-protease and low-amylase *Bacillus subtilis* strain (e.g. strain SHA273 mentioned in WO 92/11357).

10 Construction of variants T183\* + G184\* and R181\* + G182\*: The PCR overlap extension mutagenesis method is used to construct these variants (Higuchi et al., 1988). The mutagenic oligoneucleotides are synthesized using a mixture (equal parts) of C and G in one position; two different mutations can therefore be constructed by this procedure. An approximately 300 bp DNA  
15 fragment of pTVB106 is amplified in a PCR reaction A using primers #7113 and mutagenic primer #7449. In a similar PCR reaction B, an approximately 400 bp DNA fragment is amplified using primers Y296 and #3811. The complete DNA fragment spanning the mutation site (amino acids 181-184) from primer #7113 to primer Y296 is amplified in PCR C using these primers and purified DNA  
20 fragments from reactions A and B.

PCR C DNA is digested with restriction endonucleases BstEII and AflIII and the 480 bp fragment is ligated with plasmid pTVB106 digested with the same enzymes and transformed into a low-protease and low-amylase *B. subtilis* strain (e.g. strain SHA273 mentioned in WO 92/11357). Sequencing of plasmid DNA  
25 from these transformants identifies the two correct mutations: i.e. R181\* + G182\* and T183\* + G184\*.

Primers:

#7113:

5' GCT GCG GTG ACC TCT TTA AAA AAT AAC GGC 3'

Y296:

5 5' CC ACC GCT ATT AGA TGC ATT GTA C 3'

#6779

5' CTT ACG TAT GCA GAC GTC GAT ATG GAT CAC CC 3'

#6778

5' G ATC CAT ATC GAC GTC TGC ATA CGT AAG ATA GTC 3'

10 #3811

5' TT A(C/G)G GGC AAG GCC TGG GAC TGG 3'

#7449

5'C CCA GGC CTT GCC C(C/G)T AAA TTT ATA TAT TTT GTT TTG 3'

### EXAMPLE 3

15 Determination of oxidation stability of variant M202T relative to the parent  $\alpha$ -amylase having the amino sequence shown in SEQ ID No. 1

The enzyme variant to be tested (in this case M202T) was purified to homogeneity in a manner analogous to that described above for the parent  $\alpha$ -amylase having the amino acid sequence shown in SEQ ID No. 1. The buffer was  
20 changed to 50mM Britton-Robinson buffer (50 mM acetic acid, 50 mM phosphoric acid, 50 mM boric acid, 0.1 mM  $\text{CaCl}_2$ , pH adjusted to the value of interest with NaOH), pH 9.0. Hydrogen peroxide was added to the enzyme solution to give a final concentration of 200mM  $\text{H}_2\text{O}_2$ , and the solution was then incubated at 40°C in a water bath.

After 2, 4, 6, 10, 15 and 30 minutes of incubation the residual  $\alpha$ -amylase activity was measured using the Phadebas assay described above. The residual activity in the samples was measured using 50mM Britton-Robinson buffer, pH 7.3, at 37°C (see Novo analytical publication AF207-1/1, available on request from Novo Nordisk A/S). The decline in activity was measured relative to a reference sample of the same enzyme at 0 minutes which was not incubated with hydrogen peroxide (100% activity).

The percentage of initial activity as a function of time is shown in the table below for the parent enzyme and for the variant in question.

10	Time in min.	SEQ ID No.1	variant M202T
	0	100	100
	4	57	90
	6	42	67
	10	31	52
15	15	14	37
	30	2	24

The variant M202T clearly exhibits significantly improved stability towards oxidation relative to the parent  $\alpha$ -amylase in question.

Determination of thermal stability of the deletion variant T183\* + G184\* relative to the parent  $\alpha$ -amylase having the amino sequence shown in SEQ ID No. 1

The enzyme variant to be tested (in this case T183\* + G184\*) was purified to homogeneity in a manner analogous to that described above for the parent  $\alpha$ -

amylase having the amino acid sequence shown in SEQ ID No. 1. The buffer was changed to 50mM Glycine buffer, 0,1mM CaCl<sub>2</sub>, pH 10,5. The enzyme solution was then incubated in a water bath at 55°C.

After 5, 10, 15 and 30 minutes of incubation the residual activity was measured using the Phadebas assay described above. The residual activity in the samples was measured using 50mM Glycine buffer, pH 7,3, 37°C (see Novo analytical publication AF207-1/1, available on request from Novo Nordisk A/S). The decline in activity was measured relative to a reference sample of the same enzyme at 0 minutes which was not incubated (100% activity).

10	min.	SEQ ID No. 1	T183* + G184*
	0	100%	100%
	5	77%	89%
	10	68%	89%
	15	70%	85%
15	30	37%	86%

The variant T183\* + G184\* clearly exhibits significantly improved stability at 55°C relative to the parent  $\alpha$ -amylase in question.

**REFERENCES CITED IN THE SPECIFICATION**

Suzuki et al., the Journal of Biological Chemistry, Vol. 264, No. 32, Issue of November 15, pp. 18933-18938 (1989).

Hudson et al., Practical Immunology, Third edition (1989), Blackwell Scientific Publications.

Lipman and Pearson (1985) Science 227, 1435.

Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor, 1989.

S.L. Beaucage and M.H. Caruthers, Tetrahedron Letters 22, 1981, pp. 1859-10 1869.

Matthes et al., The EMBO J. 3, 1984, pp. 801-805.

R.K. Saiki et al., Science 239, 1988, pp. 487-491.

Morinaga et al., 1984, Biotechnology 2, pp. 646-639.

Nelson and Long, Analytical Biochemistry 180, 1989, pp. 147-151.

15 Hunkapiller et al., 1984, Nature 310, pp. 105-111.

R. Higuchi, B. Krummel, and R.K. Saiki (1988). A general method of *in vitro* preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions. Nucl. Acids Res. 16, pp. 7351-7367.

Dubnau et al., 1971, J. Mol. Biol. 56, pp. 209-221.

Gryczan et al., 1978, J. Bacteriol. 134, pp. 318-329.

S.D. Erlich, 1977, Proc. Natl. Acad. Sci. 74, pp. 1680-1682.

Boel et al., 1990, Biochemistry 29, pp. 6244-6249.



## SEQ ID No. 1

1

CAT CAT AAT GGA ACA AAT GGT ACT ATG ATG CAA TAT TTC GAA TGG TAT TTG CCA AAT GAC  
H H N G T N G T M M Q Y F E W Y L P N D

21

GGG AAT CAT TGG AAC AGG TTG AGG GAT GAC GCA GCT AAC TTA AAG AGT AAA GGG ATA ACA  
G N H W N R L R D D A A N L K S K G I T

41

GCT GTA TGG ATC CCA CCT GCA TGG AAG GGG ACT TCC CAG AAT GAT GTA GGT TAT GGA GCC  
A V W I P P A W K G T S Q N D V G Y G A

61

TAT GAT TTA TAT GAT CTT GGA GAG TTT AAC CAG AAG GGG ACG GTT CGT ACA AAA TAT GGA  
Y D L Y D L G E F N Q K G T V R T K Y G

81

ACA CGC AAC CAG CTA CAG GCT GCG GTG ACC TCT TTA AAA AAT AAC GGC ATT CAG GTA TAT  
T R N Q L Q A A V T S L K N N G I Q V Y

101

GGT GAT GTC GTC ATG AAT CAT AAA GGT GGA GCA GAT GGT ACG GAA ATT GTA AAT GCG GTA  
G D V V M N H K G G A D G T E I V N A V

121

GAA GTG AAT CGG AGC AAC CGA AAC CAG GAA ACC TCA GGA GAG TAT GCA ATA GAA GCG TGG  
E V N R S N R N Q E T S G E Y A I E A W

141

ACA AAG TTT GAT TTT CCT GGA AGA GGA AAT AAC CAT TCC AGC TTT AAG TGG CGC TGG TAT  
T K F D F P G R G N N H S S F K W R W Y

161

CAT TTT GAT GGG ACA GAT TGG GAT CAG TCA CGC CAG CTT CAA AAC AAA ATA TAT AAA TTC  
H F D G T D W D Q S R Q L Q N K I Y K F

181

AGG GGA ACA GGC AAG GCC TGG GAC TGG GAA GTC GAT ACA GAG AAT GGC AAC TAT GAC TAT  
R G T G K A W D W E V D T E N G N Y D Y

201

CTT ATG TAT GCA GAC GTG GAT ATG GAT CAC CCA GAA GTA ATA CAT GAA CTT AGA AAC TGG  
L M Y A D V D M D H P E V I H E L R N W

221

GGA GTG TGG TAT ACG AAT ACA CTG AAC CTT GAT GGA TTT AGA ATA GAT GCA GTG AAA CAT  
G V W Y T N T L N L D G F R I D A V K H

241

ATA AAA TAT AGC TTT ACG AGA GAT TGG CTT ACA CAT GTG CGT AAC ACC ACA GGT AAA CCA  
I K Y S F T R D W L T H V R N T T G K P

261

ATG TTT GCA GTG GCT GAG TTT TGG AAA AAT GAC CTT GGT GCA ATT GAA AAC TAT TTG AAT  
M F A V A E F W K N D L G A I E N Y L N

281

AAA ACA AGT TGG AAT CAC TCG GTG TTT GAT GTT CCT CTC CAC TAT AAT TTG TAC AAT GCA  
K T S W N H S V F D V P L H Y N L Y N A

301

TCT AAT AGC GGT GGT TAT TAT GAT ATG AGA AAT ATT TTA AAT GGT TCT GTG GTG CAA AAA  
S N S G G Y Y D M R N I L N G S V V Q K

321

CAT CCA ACA CAT GCC GTT ACT TTT GTT GAT AAC CAT GAT TCT CAG CCC GGG GAA GCA TTG  
H P T H A V T F V D N H D S Q P G E A L

341

GAA TCC TTT GTT CAA CAA TGG TTT AAA CCA CTT GCA TAT GCA TTG GTT CTG ACA AGG GAA  
E S F V Q Q W F K P L A Y A L V L T R E

361

CAA GGT TAT CCT TCC GTA TTT TAT GGG GAT TAC TAC GGT ATC CCA ACC CAT GGT GTT CCG  
Q G Y P S V F Y G D Y Y G I P T H G V P

381

GCT ATG AAA TCT AAA ATA GAC CCT CTT CTG CAG GCA CGT CAA ACT TTT GCC TAT GGT ACG  
A M K S K I D P L L Q A R Q T F A Y G T

401

CAG CAT GAT TAC TTT GAT CAT CAT GAT ATT ATC GGT TGG ACA AGA GAG GGA AAT AGC TCC  
Q H D Y F D H H D I I G W T R E G N S S

421

CAT CCA AAT TCA GGC CTT GCC ACC ATT ATG TCA GAT GGT CCA GGT GGT AAC AAA TGG ATG  
H P N S G L A T I M S D G P G G N K W M

441

TAT GTG GGG AAA AAT AAA GCG GGA CAA GTT TGG AGA GAT ATT ACC GGA AAT AGG ACA GGC  
Y V G K N K A G Q V W R D I T G N R T G

261

ACC GTC ACA ATT AAT GCA GAC GGA TGG GGT AAT TTC TCT GTT AAT GGA GGG TCC GTT TCG  
T V T I N A D G W G N F S V N G G S V S

481

GTT TGG GTG AAG CAA TAA  
V W V K Q \*

**CLAIMS**

1. A variant of a parent  $\alpha$ -amylase, which parent  $\alpha$ -amylase: (i) has the amino acid sequence shown in SEQ ID No. 1; or (ii) displays at least 80% homology with said amino acid sequence, and/or displays immunological cross-reactivity  
5 with an antibody raised against an  $\alpha$ -amylase having said amino acid sequence, and/or is encoded by a DNA sequence which hybridizes with the same probe as the DNA sequence encoding an  $\alpha$ -amylase having said amino acid sequence, which latter DNA sequence is shown in SEQ ID No. 1; in which variant:  
(a) at least one amino acid residue of said parent  $\alpha$ -amylase has been deleted;  
10 and/or  
(b) at least one amino acid residue of said parent  $\alpha$ -amylase has been replaced by a different amino acid residue; and/or  
(c) at least one amino acid residue has been inserted relative to said parent  $\alpha$ -amylase;  
15 said variant having  $\alpha$ -amylase activity and exhibiting at least one of the following properties relative to said parent  $\alpha$ -amylase: increased thermostability; increased stability towards oxidation; reduced  $\text{Ca}^{++}$  dependency.
2. A variant according to claim 1, wherein at least one oxidizable amino acid residue of said parent  $\alpha$ -amylase has been deleted or has been replaced by a  
20 different amino acid residue which is less susceptible to oxidation than said oxidizable amino acid residue.
3. A variant according to claim 2, wherein said oxidizable amino acid residue is selected from the group consisting of methionine, tryptophan, cysteine and tyrosine.
- 25 4. A variant according to claim 2 or 3, wherein said oxidizable amino acid residue is a methionine which is, or which is equivalent to, M9, M10, M105, M202, M208, M261, M309, M382, M430 or M440 of the amino acid sequence shown in SEQ ID No. 1.

5. A variant according to claim 4, comprising a methionine substitution which is, or which is equivalent to, one of the following substitutions in the amino acid sequence shown in SEQ ID No. 1: M9L; M10L; M202L,T,F,I,V; M261L; M309L; M382L; M430L; M440L.
- 5 6. A variant according to any one of claims 3-5, wherein a said methionine residue has been replaced by threonine.
7. A variant according to any one of the preceding claims, wherein at least one amino acid which is, or which is equivalent to, F180, R181, G182, T183, G184 or K185 of the amino acid sequence shown in SEQ ID No. 1 has been deleted.
- 10 8. A variant according to claim 7, wherein the deleted amino acids are, or are equivalent to, any two of said amino acid residues.
9. A variant according to claim 8, wherein the deletions are, or are equivalent to, R181\* + G182\*; or T183\* + G184\*.
10. A variant according to any one of the preceding claims, comprising an amino  
15 acid substitution which is, or which is equivalent to, one of the following substitutions in the amino acid sequence shown in SEQ ID No. 1: P260E; R124P; M105F,I,L,V; M208F,W,Y; L217I; V206I,L,F.
11. A variant according to any one of the preceding claims, comprising an amino  
acid substitution which is, or which is equivalent to, one of the following  
20 substitutions in the amino acid sequence shown in SEQ ID No. 1: Y243F; K108R; K179R; K239R; K242R; K269R; D163N; D188N; D192N; D199N; D205N; D207N; D209N; E190Q; E194Q; N106D.
12. A DNA construct comprising a DNA sequence encoding an  $\alpha$ -amylase variant according to any one of claims 1-11.

13. A recombinant expression vector which carries a DNA construct according to claim 12.
14. A cell which is transformed with a DNA construct according to claim 12 or a vector according to claim 13.
- 5 15. A cell according to claim 14, which is a microorganism.
16. A cell according to claim 15, which is a bacterium or a fungus.
17. A cell according to claim 16, which is a grampositive bacterium such as *Bacillus subtilis*, *Bacillus licheniformis*, *Bacillus lentus*, *Bacillus brevis*, *Bacillus stearothermophilus*, *Bacillus alkalophilus*, *Bacillus amyloliquefaciens*, *Bacillus*  
10 *coagulans*, *Bacillus circulans*, *Bacillus lautus*, *Bacillus thuringiensis* or *Streptomyces lividans* or *Streptomyces murinus*, or a gramnegative bacterium such as *E.coli*.
18. A method of producing an  $\alpha$ -amylase variant according to any one of claims 1-11, wherein a cell according to any one of claims 14-17 is cultured under  
15 conditions conducive to the production of the  $\alpha$ -amylase variant, and the  $\alpha$ -amylase variant is subsequently recovered from the culture.
19. Use of an  $\alpha$ -amylase variant according to any one of claims 1-11 for washing and/or dishwashing.
20. A detergent additive comprising an  $\alpha$ -amylase variant according to any one  
20 of claims 1-11, optionally in the form of a non-dusting granulate, stabilised liquid or protected enzyme.
21. A detergent additive according to claim 20, comprising 0.02-200 mg of enzyme protein per gram of the additive.

22. A detergent additive according to claim 20 or 21, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.

23. A detergent composition comprising an  $\alpha$ -amylase variant according to any  
5 one of claims 1-11.

24. A detergent composition according to claim 23, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.

25. A manual or automatic dishwashing detergent composition comprising an  
10  $\alpha$ -amylase variant according to any one of claims 1-11.

26. A dishwashing detergent composition according to claim 25, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, another amylolytic enzyme and/or a cellulase.

27. A manual or automatic laundry washing composition comprising an  $\alpha$ -amylase  
15 variant according to any one of claims 1-11.

28. A laundry washing composition according to claim 27, which additionally comprises another enzyme such as a protease, a lipase, a peroxidase, an amylolytic enzyme and/or a cellulase.

29. Use of an  $\alpha$ -amylase variant according to any one of claims 1-11 for textile  
20 desizing.




Fig. 1